Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VVX001 in Healthy and Chronic HBV Patients
NCT03625934Phase 2Unknown
- Sponsor
- Viravaxx AG
- Start
- Aug 2018
- Primary completion
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of VVX001 in hepatitis B (HBV), sponsored by Viravaxx AG. Status: unknown.
02
Drugs
VVX001
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03625934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03625934.